Photodynamic therapy for actinic keratosis in organ transplant patients

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages 57-66

  Basset Seguin, N ^a   Baumann Conzett, K ^b   Gerritsen, M J P ^c   Gonzalez, H ^d   Haedersdal, M ^e   Hofbauer, G F L ^b   Aguado, L ^f   Kerob, D ^g   Lear, J T ^h   Piaserico, S ⁱ   Ulrich, C ^j  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e BISPEBJERG HOSPITAL   (Denmark)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g Galderma International   (France)

^h MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD;

ACTINIC KERATOSIS; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTACT DERMATITIS; DERMATOLOGIST; DISEASE DURATION; GRAFT RECIPIENT; HUMAN; HYPERKERATOSIS; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; NON MELANOMA SKIN CANCER; ORGAN TRANSPLANT RECIPIENT; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; STANDARDIZATION; ULTRAVIOLET RADIATION; WART VIRUS;

ADULT; AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; UNNECESSARY PROCEDURES;

EID: 84872873849     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04356.x     Document Type: Article

References (104)

1. Traywick C, O'Reilly FM,. Management of skin cancer in solid organ transplant recipients. Dermatol Ther 2005; 18: 12-18.
2. Keller B, Braathen LR, Marti HP, Hunger RE,. Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern. Swiss Med Wkly 2010; 140: w13036.
3. Berg D, Otley CC,. Skin cancer in organ transplant recipients: epidemiology, pathogenesis and management. J Am Acad Dermatol 2002; 47: 1-17.
4. Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-186.
5. Lober BA, Lober CW, Accola J,. Actinic keratosis is squamous cell carcinoma. J Am Acad Dermatol 2000; 43: 881-882.
6. Guenthner ST, Hurwitz RM, Buckel LJ, Gray HR,. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation. J Am Acad Dermatol 1999; 41: 443-448.
7. Piaserico S, Belloni Fortina A, Rigotti P, et al. Topical photodynamic therapy of actinic keratosis in renal transplant patients. Transplant Proc 2007; 39: 1847-1850.
8. Ackerman AB, Mones JM,. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22.
9. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S,. Skin cancer in organ transplant recipients-where do we stand today? Am J Transplantation 2008; 8: 2192-2198.
10. Ulrich C, Jurgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161: 78-84.
11. Lebwohl MG, Rosen T, Stockfleth E,. The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic options. Cutis 2010; 86: Suppl.1-Suppl.11.
12. Queille S, Luron L, Spatz A, et al. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis 2007; 28: 724-731.
13. Yarosh D, Canning M, Teicher D, Brown D,. After sun reversal of DNA damage: enhancing skin repair. Mutat Res 2005; 571: 57-64.
14. Yarosh D, Pena A, Nay S, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-1025.
15. Andre N, Roquelaure B, Conrath J,. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses 2004; 63: 647-652.
16. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
17. Wu X, Nguyen BC, Dziunycz P, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010; 465: 368-372.
18. O'Donovan P, Perrett C, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874.
19. Guba M, Graeb C, Jauch KW, Geissler EK,. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777-1782.
20. Rival-Tringali A-L, Euvrard S, Decullier E, et al. Conversion from calcineurin inhibitors to sirolimus reduces vascularisation and thickness of post-transplant cutaneous squamous cell carcinomas. Anticancer Res 2009; 29: 1927-1932.
21. Euvrard S,. What is New in Immunosuppression and Transplant Medicine. Abstract S44; 19th Congress of the European Association of Dermatology and Venereology, Gothenburg, Sweden, 2010.
22. Signorell J, Hunziker T, Martinelli M, et al. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. Transplant Proc 2010; 42: 3871-3875.
23. Belloni Fortina A, Caforio ALP, Piaserico S, et al. Skin cancer in heart transplant patients: Frequency and risk factor analysis. J Heart Lung Transplant 2000; 19: 249-255.
24. Frezza EE, Fung JJ, van Thiel DH,. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-1181.
25. Caforio ALP, Belloni Fortina A, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102 (Suppl. III): III-222-III-227.
26. Bouwes-Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996; 61: 715-721.
27. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950-956.
28. Harwood CA, Proby CM,. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002; 15: 101-114.
29. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988-1996. N Engl J Med 2000; 342: 605-612.
30. Lee MM, Wick MM,. Bowen's disease. CA Cancer J Clin 1990; 40: 237-242.
31. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33: 222-229.
32. Stockfleth E, Ulrich C, Meyer T, Christophers E,. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002; 160: 251-258.
33. Webb MC, Compton F, Andrews PA, Koffman CG,. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc 1997; 29: 828-830.
34. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89: 1231-1238.
35. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093-1100.
36. Dreno B,. Skin cancers after transplantation. Nephrol Dial Transplant 2003; 18: 1052-1058.
37. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003; 139: 301-306.
38. Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-centre study. Transplant Proc 1998; 30: 1124-1126.
39. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S,. Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant 2008; 8: 2192-2198.
40. Ramsay HM, Fryer A, Hawley C, et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49: 397-406.
41. Urwin HR, Jones PW, Harden PN, et al. Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 2009; 87: 1667-1671.
42. Slaughter DP, Southwick HW, Smejkal W,. 'Field cancerization' in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 963-968.
43. Smits T, Kleinpenning MM, Blokx WAM, et al. Fluorescence diagnosis in keratinocytic intraepidermal neoplasias. J Am Acad Dermatol 2007; 57: 824-831.
44. De Berker D, McGregor JM, Hughes BR, on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of AK. Br J Dermatol 2007; 156: 222-230.
45. Einspahr J, Alberts DS, Aickin M, et al. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin. Cancer Epidemiol Biomarkers Prev 1997; 6: 583-587.
46. Ulrich C, Hackethal M, Ulrich M, et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007; 156 (Suppl. 3): 40-42.
47. Wennberg A-M, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-429.
48. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157 (Suppl. 2): 25-31.
49. ® (Graceway Pharmaceuticals, Bristol, England). Available from: URL: http://www.medicines. org.uk/emc/medicine/8.
50. Ulrich C, Johannsen A, Rowert-Huber J, et al. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010; 20: 1-7.
51. Dragieva C, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77: 115-121.
52. Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156: 320-328.
53. ® (Galderma, Paris, France). Available from: URL: http://www.medicines.org.uk/emc/medicine/ 11913/SPC/metvix%20160%20mg~g%20cream/.
54. ® (DUSA Pharmaceuticals, Wilmington, USA). Available from: URL: http://www.rxlist.com/ levulan-kerastick-drug.htm.
55. Dragieva C, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200.
56. Willey A, Mehta S, Lee PK,. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg 2010; 36: 652-658.
57. Perrett CM, Tan SK, Cerio R, et al. Treatment of a basal cell carcinoma with topical methylaminolaevulinate photodynamic therapy in an organ-transplant recipient. Clin Exp Dermatol 2006; 31: 146-147.
58. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA,. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-28.
59. De Graaf YG, Kennedy C, Wolterbeek R, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-574.
60. Garg AD, Nowis D, Golab J, Agostinis P,. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010; 15: 1050-1071.
61. Kosmidis M, Dziunycz P, Suárez-Fariñas M, et al. Immunosuppression affects CD4 + mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients. J Immunother 2010; 33: 538-546.
62. Mühleisen B, Petrov I, Gächter T, et al. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123 + and FOXP3 + cells in the perineoplastic inflammatory infiltrate. Histopathology 2009; 55: 67-76.
63. Gerritsen MJ, Smits T, Kleinpenning MM, et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193-202.
64. Berroeta L, Clark C, Dawe RS, et al. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol 2007; 157: 401-403.
65. Soler AM, Warloe T, Berner A, Giercksky KE,. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145: 467-471.
66. Souza CS, Neves AB, Felício LA, et al. Optimized photodynamic therapy with systemic photosensitizer following debulking technique for nonmelanoma skin cancers. Dermatol Surg 2007; 33: 194-198.
67. Thissen MR, Schroeter CA, Neumann HA,. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000; 142: 338-339.
68. Kleinpenning MM, Kanis JH, Smits T, et al. The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis. J Dermatolog Treat 2010; 21: 245-251.
69. Ibbotson SH, Jong C, Lesar A, et al. Characteristics of 5-aminolaevulinic acid-induced protoporphyrin IX fluorescence in human skin in vivo. Photodermatol Photoimmunol Photomed 2006; 22: 105-110.
70. Ladermann J, Ilgevicius A, Zurbau O, et al. Penetration studies of topically applied substances: optical determination of the amount of stratum corneum removed by tape stripping. J Biomed Opt 2006; 11: 054026.
71. Haedersdal M, Sakamoto F, Farinelli WA, et al. Fractional CO2 laser-assisted drug delivery. Las Surg Med 2010; 42: 113-122.
72. Fang JY, Lee WR, Shen SC, et al. Enhancement of topical 5-aminolaevulinic acid delivery by erbium:YAG laser and microdermabrasion: a comparison with iontophoresis and electroporation. Br J Dermatol 2004; 151: 132-140.
73. Juzeniene A, Juzenas P, Kaalhus O, et al. Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin. Photochem Photobiol 2002; 76: 452-456.
74. van den Akker JT, Boot K, Vernon DI, et al. Effect of elevating the skin temperature during topical ALA application on in vitro ALA penetration through mouse skin and in vivo PpIX production in human skin. Photochem Photobiol Sci 2004; 3: 263-267.
75. Juzeniene A, Juzenas P, Bronshtein I, et al. The influence of temperature on photodynamic cell killing in vitro with 5-aminolevulinic acid. J Photochem Photobiol B 2006; 84: 161-166.
76. Mikolajewska P, Donnelly RF, Garland MJ, et al. Microneedle pre-treatment of human skin improves 5-aminolevulinic acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. Pharm Res 2010; 27: 2213-2220.
77. Schleier P, Hyckel P, Berndt A, et al. Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol 2004; 130: 279-284. http://www.ncbi.nlm.nih.gov/pubmed? term=%22Schleier%20P%22%5BAuthor%5D
78. Bagazgoitia L, Cuevas Santos J, Juarranz A, Jaen P,. Photodynamic therapy reduces the histologic features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144-151.
79. Brown VL, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant patients. Arch Dermatol 2005; 141: 985-993.
80. Steinbauer JM, Schreml S, Babilas P, et al. Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci 2009; 8: 1111-1116.
81. Grapengiesser S, Ericson M, Gudmundsson F, et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27: 493-497.
82. Arits AHMM, van der Weert MM, Nelemans PJ, Kelleners-Smeets NWJ,. Pain during photodynamic therapy: uncomfortable and unpredictable. J Eur Acad Dermatol Venereol 2010; 24: 1452-1457.
83. Warren CB, Karai LJ, Vidimos A, Maytin EV,. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol 2009; 61: 1033-1043.
84. Sandberg C, Stenquist B, Rosdahl I, et al. Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol 2006; 86: 404-408.
85. Holmes MV, Dawe RS, Ferguson J, Ibbotson SH,. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy. Br J Dermatol 2004; 150: 337-340.
86. Langan SM, Collins P,. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol 2006; 154: 146-149.
87. Skiveren H, Haedersdal M, Philipsen PA, et al. Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized double-blind, placebo-controlled study. Acta Derm Venereol 2006; 86: 409-411.
88. Pagliaro J, Elliott T, Bulsara M, et al. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease: an effective addition to treatment: a pilot study. Dermatol Surg 2004; 30: 63-66.
89. Wiegell SR, Haedersdal M, Wulf HC,. Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomised clinical study. Acta Derm Venereol 2009; 89: 145-149.
90. Halldin CB, Paoli J, Sandberg C, et al. Transcutaneous electrical nerve stimulation for pain relief during photodynamic therapy of actinic keratoses. Acta Derm Venereol 2008; 88: 311-312.
91. Wiegell SR, Haedersdal M, Philipsen PA, et al. Continuous activation of PPIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratosis: a randomized, controlled, single-blinded study. Br J Dermatol 2008; 158: 740-746.
92. Wiegell SR, Haedersdal M, Eriksen P, Wulf HC,. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol 2009; 160: 1308-1314.
93. Wiegell SR, Fabricius S, Stender IM, et al. A randomized, multi-centre study of directed daylight exposure times of 11/2 versus 21/2 hours in daylight mediated photodynamic therapy with methyl aminolevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 2011; 164: 1083-1090.
94. Halldin CB, Paoli J, Sandberg C, et al. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol 2009; 160: 795-800.
95. Paoli J, Halldin C, Ericson MB, Wennberg AM,. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol 2008; 33: 559-564.
96. Schmook T, Budde K, Ulrich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transpl 2005; 20: 220-221.
97. Hohwy T, Andersen KE, Sølvsten H, Sommerlund M,. Allergic contact dermatitis to methyl aminolevulinate after photodynamic therapy in 9 patients. Contact Dermatitis 2007; 57: 321-323.
98. Korshoj S, Solvsten H, Erlandsen M, Sommerlund M,. Frequency of sensitisation to methyl aminolaevulinate after photodynamic therapy. Contact Dermatitis 2009; 60: 320-324.
99. Gollnick So, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003; 88: 1772-1779.
100. Matthews YJ, Damian DL,. Topical photodynamic therapy is immunosuppressive in humans. Br J Dermatol 2010; 162: 637-641.
101. Nobbe S, Trüeb RM, French LE, Hofbauer GFL,. Herpes simplex virus reactivation as a complication of photodynamic therapy. Photodermatol Photoimmunol Photomed 2011; 27: 51-52.
102. Frost GA, Halliday GM, Damian DL,. Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery. J Invest Dermatol 2011; 131: 962-968.
103. Mroz P, Szokalska A, Wu MX, Hamblin MR,. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS ONE 2010; 5: e15194.
104. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH,. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730.